Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
Primary Objective:
To evaluate the efficacy of dupilumab administered every 2 weeks in patients with moderate or severe Chronic Obstructive Pulmonary Disease (COPD) as measured by
Secondary Objectives:
To evaluate the effect of dupilumab administered every 2 weeks on
Full description
Approximately 68 weeks including a 4-week screening period, a 52-week treatment period, and 12 weeks of follow-up
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Participants with a physician diagnosis of COPD who meet the following criteria at screening:
Evidence of Type 2 inflammation: Patients with blood eosinophils ≥300 cells/microliter at Visit 1.
Exclusion criteria
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Primary purpose
Allocation
Interventional model
Masking
935 participants in 2 patient groups, including a placebo group
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal